Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JBPOS0254
- Development stage
- Preclinical
- Lead developer
- Bio-Pharm Solutions
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JBPOS0254 is a small molecule therapeutic candidate currently in preclinical development by Bio-Pharm Solutions. It is being investigated for the treatment of epilepsy, Complex Regional Pain Syndrome (CRPS), and various pain management indications. The compound is part of Bio-Pharm Solutions' CNS-focused pipeline, which leverages small molecule chemistry to modulate neuronal excitability. While specific target details for JBPOS0254 have not been publicly disclosed to the same extent as the company's lead programs (such as the mGluR antagonist JBPOS0101), it is positioned as a potential treatment for refractory neurological and neuropathic conditions.
Beyond the preview
Go deeper on JBPOS0254.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JBPOS0254.